# Phase II

From Test Kits to First‑in‑Class Drugs: Hotgen’s Bid to Anchor ‘Healthy China’ in Home‑grown Biotech

Hotgen Biotech is pursuing a dual diagnostics‑and‑innovative‑drug strategy to back China’s Healthy China goals, advancing an antibody for acute myocardial infarction, SGC001, into Phase II. The effort exemplifies China’s broader shift from following foreign pharmaceutical models to developing first‑in‑class domestic innovations, but faces clinical, manufacturing and regulatory hurdles before it can transform national health and global competitiveness.